CyanVac, Immuno Technologies announce long-lasting Lyme vaccine results
CyanVac LLC, a trailblazer in intranasal vaccine technology, in collaboration with Immuno Technologies, Inc., a leader in vaccines and diagnostics for Lyme disease, has unveiled promising preclinical data in NPJ Vaccines. The data reveal that mice inoculated with a Parainfluenza Virus 5 (PIV5)-based intranasal vaccine show long-lasting neutralizing antibody responses and extended protection of up to 15 months against various strains of Borrelia burgdorferi, the bacteria responsible for Lyme disease.
A Leap in Lyme Disease Prevention
The study’s findings underscore the PIV5 platform’s potential to elicit durable immune responses against vector-borne pathogens, significantly expanding its application beyond previously studied diseases. “Vaccines developed using our proprietary PIV5-based platform have generated long-term immune responses for a range of pathogens in preclinical models and have demonstrated very encouraging human results in RSV and COVID-19,” stated Biao He, founder and CEO of CyanVac. This research represents a significant stride in Lyme disease vaccine development, a critical public health need with over 450,000 people affected annually in the U.S. alone.
CyanVac and Immuno Technologies report long-lasting Lyme vaccine results
The Urgent Need for a Lyme Disease Vaccine
Lyme disease, the most prevalent vector-borne illness in the U.S. and Europe, poses a significant public health challenge, particularly in the Northeast, Mid-Atlantic, and Midwest regions of the U.S. Although most cases can be treated with antibiotics, a subset of infected individuals experience a progressive and potentially debilitating form of the disease. The absence of a licensed vaccine amplifies the urgency for innovative solutions like the PIV5-based intranasal vaccine.
Superior Protection and Ease of Administration
The PIV5-based Lyme vaccine not only demonstrated superior protection against ticks carrying up to 19 different B. burgdorferi strains compared to a subcutaneous vaccine control but also maintained higher levels of neutralizing antibodies. This indicates a pivotal advantage in protection longevity and ease of administration. “These preclinical data showing long-lasting protection against infection after a prime-boost immunization are extremely encouraging,” added Dr. He, highlighting the potential of the PIV5 platform to address the gap in Lyme disease prevention.
A Bright Future for Lyme Disease Prevention
The collaborative effort between CyanVac LLC and Immuno Technologies, Inc. paves the way for a groundbreaking approach to Lyme disease vaccination. With a focus on harnessing the immune system’s full breadth through intranasal delivery, this research could lead to more effective and accessible vaccines for Lyme disease and beyond. As CyanVac and Immuno Technologies continue to pursue market approval, the potential to improve public health and quality of life for those at risk of Lyme disease is immense.